S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

$1.54
+0.05 (+3.36%)
(As of 03/27/2024 ET)
Today's Range
$1.46
$1.54
50-Day Range
$1.21
$1.86
52-Week Range
$0.66
$1.95
Volume
30,835 shs
Average Volume
84,117 shs
Market Capitalization
$44.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Candel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
484.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Candel Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.09) to ($0.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.86 out of 5 stars

Medical Sector

383rd out of 939 stocks

Biological Products, Except Diagnostic Industry

56th out of 154 stocks

CADL stock logo

About Candel Therapeutics Stock (NASDAQ:CADL)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

CADL Stock Price History

CADL Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Candel's Can-3110 Receives FDA Fast Track Designation
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Candel Receives FDA Fast Track Designation For CAN-2409 Plus Prodrug
Immuno-oncology firm Candel cuts its workforce in half
Candel Therapeutics to Cut Workforce in Half
Candel Therapeutics Inc CADL
Candel Therapeutics GAAP EPS of -$0.29
Recap: Candel Therapeutics Q3 Earnings
See More Headlines
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/27/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CADL
Fax
N/A
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+484.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,790,000.00
Pretax Margin
-102,990.34%

Debt

Sales & Book Value

Annual Sales
$120,000.00
Book Value
$1.65 per share

Miscellaneous

Free Float
16,022,000
Market Cap
$44.54 million
Optionable
Not Optionable
Beta
0.96
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Paul-Peter Tak FMEDSCI (Age 64)
    M.D., Ph.D., President, CEO & Director
    Comp: $1.16M
  • Dr. Estuardo Aguilar-Cordova Inf. (Age 65)
    M.D., Ph.D., Founder & Director
    Comp: $35.08k
  • Dr. Seshu Tyagarajan Ph.D. (Age 57)
    Chief Technical & Development Officer
    Comp: $335.27k
  • Dr. Francesca Barone M.D. (Age 46)
    Ph.D., Chief Scientific Officer
    Comp: $518.91k
  • Mr. Charles Schoch (Age 39)
    Interim CFO, VP of Finance & Corporate Controller
  • Ms. Ileen B. Winick
    Chief People Officer
  • Ms. Susan Stewart J.D. (Age 62)
    L.L.M., Chief Regulatory Officer
  • Dr. William Garrett Nichols M.D. (Age 55)
    M.S., Chief Medical Officer

CADL Stock Analysis - Frequently Asked Questions

Should I buy or sell Candel Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CADL shares.
View CADL analyst ratings
or view top-rated stocks.

What is Candel Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price targets for Candel Therapeutics' stock. Their CADL share price targets range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 484.4% from the stock's current price.
View analysts price targets for CADL
or view top-rated stocks among Wall Street analysts.

How have CADL shares performed in 2024?

Candel Therapeutics' stock was trading at $1.47 on January 1st, 2024. Since then, CADL shares have increased by 4.8% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

Are investors shorting Candel Therapeutics?

Candel Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 147,300 shares, a drop of 24.7% from the February 29th total of 195,600 shares. Based on an average trading volume of 89,200 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.0% of the company's shares are sold short.
View Candel Therapeutics' Short Interest
.

When is Candel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CADL earnings forecast
.

When did Candel Therapeutics IPO?

Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are Candel Therapeutics' major shareholders?

Candel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.47%), Vanguard Group Inc. (1.47%), Baystate Wealth Management LLC (0.27%) and Citadel Advisors LLC (0.06%). Insiders that own company stock include Francesca Barone, Jason Amello, Joseph C Papa, Paul Peter Tak and Seshu Tyagarajan.
View institutional ownership trends
.

How do I buy shares of Candel Therapeutics?

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CADL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners